Mirum Pharmaceuticals Advances Rare Disease Therapies at Upcoming Investor Conferences

Mirum Pharmaceuticals Strengthens Commitment to Rare Disease Therapies with Upcoming Conferences

Mirum Pharmaceuticals, Inc. is poised to showcase its advancements in rare disease therapies at several key investor conferences. The company, specializing in treatments for orphan diseases, will participate in the Stifel 2024 Healthcare Conference on November 19, the 7th Annual Evercore HealthCONx Conference on December 3, and Citi’s 2024 Global Healthcare Conference on December 4. These platforms serve not only to highlight Mirum's innovative approaches but also to engage with stakeholders who share a commitment to improving the lives of patients with rare diseases. By presenting at these events, Mirum emphasizes its strategic direction and dedication to transforming the treatment landscape for conditions that typically lack sufficient therapeutic options.

Mirum's product portfolio currently includes three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CHENODAL® (chenodiol) tablets. LIVMARLI is particularly noteworthy as an IBAT inhibitor approved for the treatment of cholestatic pruritus in patients with Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC) in both the U.S. and Europe. The company is also advancing its research through the Phase 3 EXPAND study, which investigates additional indications for LIVMARLI. This initiative underscores Mirum's commitment to ongoing research and development in the rare disease sector, aiming to optimize the therapeutic options available for patients.

The company's late-stage pipeline reflects a robust commitment to innovation, with investigational treatments like Volixibat, which has already received Breakthrough Therapy Designation for cholestatic pruritus in primary biliary cholangitis (PBC). Volixibat is currently undergoing registrational trials, showcasing Mirum's proactive stance in addressing unmet needs within the rare disease community. Furthermore, the recent submission of a new drug application for chenodiol to treat cerebrotendinous xanthomatosis (CTX) following positive Phase 3 RESTORE study results in 2023 illustrates the company’s focus on expanding its therapeutic offerings. These developments align with Mirum's mission to deliver transformative therapies for rare diseases, reinforcing its role as a leader in this critical segment of the biopharmaceutical industry.

In addition to its conference participation, Mirum Pharmaceuticals continues to enhance its presence in the rare disease market through strategic partnerships and ongoing research initiatives. The company’s focus on innovative treatments not only addresses the specific needs of patients but also contributes to the broader dialogue surrounding rare diseases and the challenges faced in developing effective therapies. As Mirum moves forward with its pipeline, the biopharmaceutical community watches closely for the potential impact of its advancements on patient care and treatment accessibility.